Complete remission of recurrent gastric cancer in a young female patient through CLDN18.2-targeted therapy (LM302) and metastatic ovarian tumor resection: a case report of refractory disease overcoming chemotherapy and immunotherapy resistance
Young patients with recurrent, metastatic gastric cancer (GC) resistant to chemotherapy and immunotherapy have poor outcomes and limited treatment options. CLDN18.2 has emerged as a promising target in GC. We report the case of a 35-year-old female who experienced recurrence with bilateral ovarian a...
Saved in:
| Main Authors: | Muyang Chen, Tongshan Wang, Anpeng Wang, Hao Zhang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1631062/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A CLDN18.2‐Targeted Nanoplatform Manipulates Magnetic Hyperthermia Spatiotemporally for Synergistic Immunotherapy in Gastric Cancer
by: Xueying Wang, et al.
Published: (2025-04-01) -
Pan-cancer analysis of CLDN18.2 shed new insights on the targeted therapy of upper gastrointestinal tract cancers
by: Jun Wu, et al.
Published: (2024-11-01) -
Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody
by: Hayat Bähr-Mahmud, et al.
Published: (2023-12-01) -
Utility of 131I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models
by: Liu Y, et al.
Published: (2025-01-01) -
MEMORY OF L.M. NEPOMNYATSCHIH
Published: (2016-02-01)